

**Supplementary Table 3.** Univariate and multivariate analysis of the correlation between variables and pathologic EPE in high risk group

Variable	No EPE (n=35)	EPE (n=48)	Univariate analysis	Multivariate analysis	p-value
			p-value	OR (95% CI)	
Age (yr)	67.3±6.1	66.9±5.1	0.757	-	-
PSA (ng/mL)	10.2±9.1	15.3±9.8	0.017	0.965 (0.841–1.107)	0.608
PSA density (ng/mL <sup>2</sup> )	0.30±0.21	0.52±0.33	0.001	74.844 (0.735–7,625.371)	0.067
Clinical ISUP on prostate needle biopsy			0.635	-	-
GGG1	1 (2.9)	1 (2.1)		-	-
GGG2	1 (2.9)	0 (0)		-	-
GGG3	2 (5.7)	1 (2.1)		-	-
GGG4	28 (80.0)	43 (89.6)		-	-
GGG5	3 (8.6)	3 (6.25)		-	-
Maximum percentage of tumor length in a positive core (%)	52.5±29.1	74.2±26.4	0.001	1.021 (0.992–1.051)	0.160
Total positive core rate (%)	26.9±15.8	44.9±22.0	<0.001	23.007 (0.315–1,680.673)	0.152
Clinical stage			0.103	-	-
T1c	12 (34.3)	6 (12.5)		-	-
T2a	11 (31.4)	12 (25.0)		-	-
T2b	5 (14.3)	8 (16.7)		-	-
T2c	3 (8.6)	7 (14.6)		-	-
T3a	4 (11.4)	13 (27.1)		-	-
T3b	0 (0)	2 (4.2)		-	-
Suspicious EPE on mpMRI	4 (10.8)	33 (89.2)	<0.001	14.214 (3.290–61.422)	<0.001

Values are presented as mean±standard deviation or number (%).

EPE, extraprostatic extension; OR, odds ratio; CI, confidence interval; PSA, prostate-specific antigen; ISUP, International Society of Urological Pathology; GGG, Gleason grade group; mpMRI, multiparametric magnetic resonance imaging.